Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A(2A) receptor agonist regadenoson

Adenosine A(2A) receptor (A(2A)R) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A(2A)R agonist regadenoson in adults with SCD. The target dose was 1.44 μg/kg/h. iNKT cell activation w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Field, Joshua J., Lin, Gene, Okam, Maureen M., Majerus, Elaine, Keefer, Jeffrey, Onyekwere, Onyinye, Ross, Ainsley, Campigotto, Federico, Neuberg, Donna, Linden, Joel, Nathan, David G.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2013
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637009/
https://ncbi.nlm.nih.gov/pubmed/23377438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-11-465963
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items